Austin, TX, May 23, 2025 (GLOBE NEWSWIRE) -- Outliyr, a performance health brand known for combining modern biohacking with ...

Cross Medical Group is pleased to announce that HydraFacial treatments are now available at the practice. A HydraFacial at their Philadelphia and Villanova offices, which is sometimes referred to as ...

Chris Taves, Chair of MediPharm, commented: “The troubling fact pattern involving three of the Dissident Nominees raises several red flags. The MediPharm Board urges its shareholders to exercise a ...

Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a Basel, 23 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) ...

U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical tri ...

(Nasdaq: SHOT) (“SHOT”, "Safety Shot”, or the “Company”), a wellness and dietary supplement company, announces its strategic plans to capitalize on the growth of Yerbae Brands Corp. (“Yerbae”) after ...

The Itovebi-based regimen is approved for the treatment of adults with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer in the United ...

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the ...

Mirdametinib is approved in the U.S. for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

BriaCell’s Phase 2 study also achieved a Clinical Benefit Rate (CBR) of 61%, outperforming ASCENT (40%) and TROPiCS-02 (34%), and an Objective Response Rate (ORR) of 14%, which matched or exceeded the ...

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market ...